# Type 2 Diabetes and MODY in Children

> Type 2 diabetes and MODY in children for NEET-PG Paediatrics, covering acanthosis nigricans, diagnostic thresholds, metformin and monogenic pointers.

- Canonical URL: https://prepelephant.com/topics/neet-pg/paediatrics/type-2-diabetes-and-mody-in-children
- Exam / course: NEET-PG · Subject: Paediatrics
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: IAP Textbook of Pediatrics; ISPAD Clinical Practice Consensus Guidelines
- How to cite: "Type 2 Diabetes and MODY in Children", PrepElephant, https://prepelephant.com/topics/neet-pg/paediatrics/type-2-diabetes-and-mody-in-children

## Direct answer

Type 2 diabetes in children is insulin resistance with progressive beta cell failure, most often in obese adolescents, and is diagnosed with the same glucose or HbA1c thresholds used in adults. Acanthosis nigricans, a strong family history and negative islet autoantibodies point towards it. Metformin is first-line for most children, while monogenic MODY is suspected when a non-obese child has diabetes across several generations.

## What you must remember

- **Acanthosis nigricans:** velvety hyperpigmentation of the neck, axillae and groin marks insulin resistance and is a strong clue to type 2 diabetes.
- **Diagnostic thresholds:** fasting plasma glucose of at least 126 mg/dL, two-hour oral glucose tolerance test value of at least 200 mg/dL, or HbA1c of at least 6.5 per cent, confirmed by repeat testing unless symptoms are classic.
- **Islet autoantibodies:** GAD, IA-2 and ZnT8 antibodies are negative in type 2 diabetes and their presence favours type 1 diabetes.
- **Metformin:** the first-line oral agent, given with lifestyle change, while insulin is started for ketosis, marked hyperglycaemia or symptoms.
- **Early complications:** nephropathy, retinopathy, hypertension, dyslipidaemia and fatty liver often appear early, because the disease is more aggressive in youth.
- **MODY:** autosomal dominant GCK, HNF1A or HNF4A defects cause mild, lifelong hyperglycaemia without obesity, and HNF1A cases often respond to sulfonylureas.
- **GCK MODY:** usually stable with a mild fasting glucose rise and typically needs no drug treatment, so it should not drive therapy.

## Type 2, MODY or type 1: reading the clues

A heavy-set 12-year-old with velvety neck skin needs more than a glucose reading to classify the diabetes. The table compares the three presentations.

| Feature | Type 2 diabetes | MODY | Type 1 diabetes |
|---|---|---|---|
| Body habitus | Usually obese, with high insulin levels | Usually not obese, with a mild glucose rise | Often lean, sometimes with weight loss at onset |
| Family history | Often strong, polygenic | Autosomal dominant, several generations | Usually absent |
| Islet autoantibodies | Negative | Negative | Usually positive |
| Acanthosis nigricans | Often present | Usually absent | Usually absent |
| Age at diagnosis | Adolescence, often with obesity | Any age, often incidental | Usually childhood |
| Ketosis at onset | Uncommon | Rare | Frequent |
| Beta cell function | Declines progressively | Defective from birth, usually stable | Lost through autoimmunity |
| Typical treatment | Lifestyle, metformin, insulin if needed | Gene-dependent, often sulfonylurea or none | Insulin |

Negative islet antibodies with obesity and acanthosis favour type 2 diabetes. A lean teenager with an affected parent and a mild, stable glucose rise raises suspicion of MODY, which genetic testing can confirm.

## Where the exam tries to catch you

Youth-onset diabetes questions test whether you can separate the three presentations rather than defaulting to type 1.

- **Trap:** assuming every young person with diabetes has type 1. — **Correct:** youth-onset type 2 is common in obese adolescents, and islet antibodies with the clinical picture separate the two.
- **Trap:** starting insulin for every new case of youth-onset type 2. — **Correct:** metformin is first-line, and insulin is reserved for ketosis, marked hyperglycaemia or symptoms.
- **Trap:** treating GCK MODY with insulin or oral drugs. — **Correct:** GCK MODY is usually stable and needs no drug, so the mild glucose rise should not drive treatment.

## Frequently asked questions

### Which criteria diagnose type 2 diabetes in an adolescent?
Type 2 diabetes is diagnosed with fasting plasma glucose of at least 126 mg/dL, a two-hour oral glucose tolerance test value of at least 200 mg/dL, or an HbA1c of at least 6.5 per cent. A random glucose of 200 mg/dL or more with classic symptoms also suffices.

### Why are islet autoantibodies tested in obese adolescents with diabetes?
Islet autoantibodies such as GAD, IA-2 and ZnT8 antibodies are typically negative in type 2 diabetes but usually positive in type 1 diabetes. Testing matters when obesity and diabetes coexist, because some obese adolescents also have autoimmune type 1 diabetes.

### When is metformin used in children with type 2 diabetes?
Metformin is the first-line oral agent for children with type 2 diabetes, given alongside lifestyle change. It is not suitable when there is ketosis or renal impairment, and insulin is preferred in those situations.

### What clinical clues suggest MODY rather than type 2 diabetes?
MODY is suggested by diabetes in a non-obese child with an affected parent or grandparent across several generations, and by absent acanthosis nigricans. Genetic testing for genes such as GCK and HNF1A confirms monogenic diabetes.